See more : Traction Uranium Corp. (TRCTF) Income Statement Analysis – Financial Results
Complete financial analysis of Core One Labs Inc. (CLABF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Core One Labs Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Hiconics Eco-energy Technology Co., Ltd. (300048.SZ) Income Statement Analysis – Financial Results
- Embrace Change Acquisition Corp. (EMCGR) Income Statement Analysis – Financial Results
- Digital Information Technologies Corporation (3916.T) Income Statement Analysis – Financial Results
- Telomir Pharmaceuticals, Inc. Common Stock (TELO) Income Statement Analysis – Financial Results
- ACI Global Corporation (ACGJ) Income Statement Analysis – Financial Results
Core One Labs Inc. (CLABF)
About Core One Labs Inc.
Core One Labs Inc. operates as a biotechnology research and technology life sciences company. The company focuses on bringing psychedelic medicines to market through novel delivery systems, psychedelic assisted psychotherapy, and API grade psilocybin manufacturing. Its CannaStrips technology produces infused strips that allow for bioavailability of cannabis constituents. The company also offers consulting, financing, and micro cultivation services, as well as operates medical and wellness clinics. In addition, it provides natural health products; and news dissemination services. The company was formerly known as Lifestyle Delivery Systems Inc. and changed its name to Core One Labs Inc. in September 2019. Core One Labs Inc. was incorporated in 2010 and is headquartered in Vancouver, Canada.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 458.54K | 431.62K | 0.00 | 5.04M | 4.08M | 191.13K | 56.09K | 58.30K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 42.20K | 38.77K | 0.00 | 5.71M | 5.77M | 0.00 | 0.00 | 1.60K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 416.34K | 392.85K | 0.00 | -669.57K | -1.69M | 191.13K | 56.09K | 56.70K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 90.80% | 91.02% | 0.00% | -13.28% | -41.40% | 100.00% | 100.00% | 97.26% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 80.34K | 627.29K | 97.91K | 1.12M | 1.12M | 2.71M | 65.08K | 59.06K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 8.36M | 5.47M | 8.13M | 7.77M | 8.67M | 1.63M | 920.79K | 304.70K | 328.25K | 459.34K | 260.27K |
| Selling & Marketing | 0.00 | 3.71M | 1.03M | 1.42M | 1.29M | 1.78M | 112.87K | 8.77K | 15.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 8.17M | 12.07M | 6.50M | 9.56M | 9.06M | 10.44M | 1.74M | 929.56K | 319.70K | 328.25K | 459.34K | 260.27K |
| Other Expenses | 0.00 | 37.30K | 614.95K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.25M | 12.64M | 7.14M | 14.67M | 10.24M | 13.16M | 2.00M | 1.11M | 430.17K | 328.25K | 459.34K | 260.27K |
| Cost & Expenses | 8.30M | 12.64M | 7.14M | 20.38M | 16.01M | 13.16M | 2.00M | 1.11M | 430.17K | 328.25K | 459.34K | 260.27K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 4.34K | 12.65K | 0.00 | 752.00 | 2.07K | 2.57K | 109.00 | 51.00 |
| Interest Expense | 1.37K | 22.25K | 16.47K | 575.41K | 130.29K | 32.65K | 0.00 | 20.01K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 42.20K | 38.77K | 206.30K | 6.09M | 54.74K | 6.92K | 187.56K | 121.51K | 110.47K | 279.94K | 0.00 | 0.00 |
| EBITDA | -7.80M | -12.13M | -6.52M | -9.25M | -11.87M | -12.97M | -1.75M | -931.17K | -319.70K | -212.13K | -459.34K | -260.27K |
| EBITDA Ratio | -1,699.99% | -2,811.50% | 0.00% | -183.52% | -290.79% | -6,786.39% | -3,125.56% | -1,597.26% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -7.84M | -12.17M | -6.52M | -15.34M | -11.92M | -12.98M | -1.94M | -1.07M | -430.17K | -492.07K | -459.34K | -260.27K |
| Operating Income Ratio | -1,709.20% | -2,820.48% | 0.00% | -304.24% | -292.13% | -6,790.01% | -3,459.98% | -1,841.30% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -8.14M | -24.82M | -39.75M | -5.74M | -1.10M | -154.02K | -925.78K | -133.99K | 2.07K | -116.12K | 109.00 | 0.00 |
| Income Before Tax | -15.98M | -37.05M | -46.90M | -21.65M | -13.15M | -13.16M | -2.87M | -1.21M | -428.10K | -441.80K | -459.23K | 0.00 |
| Income Before Tax Ratio | -3,485.36% | -8,585.16% | 0.00% | -429.47% | -322.33% | -6,887.69% | -5,110.62% | -2,069.84% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 3.00 | 59.55K | 7.71M | 386.16K | -736.22K | -535.24K | 0.00 | 20.01K | 0.00 | -166.39K | 0.00 | 260.22K |
| Net Income | -15.98M | -37.05M | -54.62M | -21.46M | -12.29M | -12.60M | -2.87M | -1.21M | -428.10K | -441.80K | -459.23K | -260.22K |
| Net Income Ratio | -3,485.36% | -8,585.16% | 0.00% | -425.72% | -301.09% | -6,590.56% | -5,110.62% | -2,069.84% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.49 | -2.57 | -10.27 | -15.25 | -10.56 | -17.52 | -8.71 | -7.79 | -12.06 | -14.11 | -14.76 | -10.65 |
| EPS Diluted | -0.49 | -2.57 | -10.27 | -15.25 | -10.56 | -17.52 | -8.71 | -7.79 | -12.06 | -14.11 | -14.76 | -10.65 |
| Weighted Avg Shares Out | 32.71M | 14.42M | 5.32M | 1.41M | 1.16M | 718.83K | 328.95K | 154.82K | 35.50K | 31.32K | 31.11K | 24.42K |
| Weighted Avg Shares Out (Dil) | 32.71M | 14.42M | 5.32M | 1.41M | 1.16M | 718.83K | 328.95K | 154.82K | 35.50K | 31.32K | 31.11K | 24.42K |
Psychedelics Company Core One Labs Dives Into Functional Mushrooms With New $3M Acquisition
Psychedelics company Core One Labs Inc. (CSE:COOL) (OTC:CLABF) is expanding into the functional mushroom space with the acquisition of New Path Laboratories Inc., a British Columbia-based company dedicated to the development and licensing of natural health products and dietary supplements....
Core One Labs Applauds the City of Seattle in Their Efforts to Decriminalize Psylocibin and Other Natural Occuring Entheogenic Drugs
VANCOUVER, British Columbia, Oct. 16, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (FWB: LD6, WKN: A3CSSU) (the “Company”) a research and technology company focused in life sciences and on bringing psychedelic medicines to market through...
Core One Labs to Present on its Proprietary Biosynthetic Psilocybin Technology at Investor Town Hall Event on August 4, 2021
VANCOUVER, British Columbia, July 17, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that Dr. Robert E.W. Hancock, the Company's Chairman, and CEO...
Core One Labs Announces Details of Consolidation to Meet Nasdaq Listing Requirements
VANCOUVER, British Columbia, July 16, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that it is pursuing a listing on the Capital Market...
REPEAT - New Psychedelic Drug Formula Believed to Work to Mitigate Neurological Damage Due to Stroke, Provisional Patent Application Filed
VANCOUVER, British Columbia, June 21, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“Akome”) has commenced the development...
New Psychedelic Drug Formula Believed to Work to Mitigate Neurological Damage Due to Stroke, Provisional Patent Application Filed
VANCOUVER, British Columbia, June 19, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“Akome”) has commenced the development...
Core One Labs Retains Canada's Highest-Ranked IP Law Firm to Assist With Patent Filings
VANCOUVER, British Columbia, June 18, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce it has retained Smart & Biggar LLP (“Smart and Biggar”) to handle all...
Core One Labs Plans Share Consolidation in Preparation of Listing its Common Shares on Nasdaq
VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) advises that in preparation of a potential listing of its common shares on the...
REPEAT - Core One Labs' Biosynthesized Psilocybin Provisional Patent Imminent
VANCOUVER, British Columbia, June 14, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce that its wholly-owned subsidiary Vocan Biotechnologies Inc. (“Vocan”), a company operating under one...
Core One Labs' Biosynthesized Psilocybin Provisional Patent Imminent
VANCOUVER, British Columbia, June 12, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce that its wholly-owned subsidiary Vocan Biotechnologies Inc. (“Vocan”), a company operating under one...
Source: https://incomestatements.info
Category: Stock Reports